Stock AYTU AYTU BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.84 USD +1.43% Intraday chart for Aytu BioPharma, Inc. +1.79% 0.00%
Feb. 14 Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Feb. 14 Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AYTU BIOPHARMA, INC. Stock Aytu BioPharma, Inc.
0.00% 15.81M
D
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.78% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.19% 233B
B+
NOVARTIS AG Stock Novartis AG
+5.41% 201B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 193B
A+
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
C+
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AYTU Stock
  4. Ratings Aytu BioPharma, Inc.